Ivabradin Krka

Ivabradine, the active ingredient in Ivabradin Krka, is a If channel inhibitor presented as an oral dosage form for oral use. It reduces heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients. It provides heart‑rate lowering without affecting myocardial contractility.

GNH USA supplies Ivabradin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics across global markets, ensuring quality and regulatory compliance.

Ivabradin Krka (ivabradine) acts on the cardiac If channel to manage ischemic heart disease and heart failure. - Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by decreasing heart rate. - Exercise‑induced angina: facilitates increased exercise tolerance by maintaining lower heart rates during activity.

Ivabradine may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: slower than intended heart rate. - Headache: mild to moderate intensity. - Dizziness: especially on standing.

Serious or Rare Side Effects: - Atrial fibrillation: new‑onset arrhythmia. - Severe bradycardia requiring intervention. - Hypotension: marked blood pressure drop. - Allergic reactions: rash, angioedema, anaphylaxis.

Before prescribing Ivabradin Krka, clinicians should consider several safety measures. - Cardiovascular assessment: evaluate baseline heart rate and rhythm prior to initiation. - Concomitant beta‑blockers: avoid excessive heart‑rate reduction when combined with other rate‑lowering agents. - CYP3A4 inhibitors: adjust therapy if strong inhibitors are used concurrently. - Visual disturbances: advise patients to report persistent luminous phenomena. - Pregnancy and breastfeeding: use only if clearly needed and prescribed by a specialist. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Ivabradine interacts with several drug classes; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine plasma levels. - Concomitant bradycardic agents (e.g., beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction. - Pacemaker dependence: ivabradine may be ineffective or cause bradyarrhythmia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may modestly raise concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensives: monitor blood pressure for additive effects.